90% efficacy for Pfizer’s COVID-19 mRNA vaccine is striking. But we need to wait for the full data - COVID-19
Guest Author • Nov 12, 2020 •
Harry Al-Wassiti, Monash University; Colin Pouton, Monash University, and Kylie Quinn, RMIT University German biotech company BioNTech and US pharmaceutical Pfizer announced on Monday promising early results from their phase 3 clinical trial for a vaccine against SARS-CoV-2, the virus that causes COVID-19. These early results are what is known as an “interim analysis”. It’s an early look at the … Read More